Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
作者： Charles Stoecker , Lindsay Kim , Ryan Gierke , Tamara Pilishvili
DOI: 10.1007/S11606-016-3651-0
关键词: Medicine 、 Pediatrics 、 Cohort study 、 Pneumonia 、 Streptococcus pneumoniae 、 Randomized controlled trial 、 Pneumococcal infections 、 Pneumococcal conjugate vaccine 、 Vaccination 、 Cost effectiveness
摘要: BACKGROUND Recently released results from a randomized controlled trial have shown that 13-valent pneumococcal conjugate vaccine (PCV13) is efficacious against vaccine-type nonbacteremic pneumonia in adults.
springer.com
paperity.org参考文章(24)
Michael V. Maciosek, Leif I. Solberg, Ashley B. Coffield, Nichol M. Edwards, Michael J. Goodman, Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. American Journal of Preventive Medicine. ,vol. 31, pp. 72- 79 ,(2006) , 10.1016/J.AMEPRE.2006.03.008
Tamara Pilishvili, Craig M. Hales, Peng-Jun Lu, Carolyn B. Bridges, Alissa O’Halloran, Lauri E. Markowitz, Walter W. Williams, Noninfluenza vaccination coverage among adults - United States, 2012. Morbidity and Mortality Weekly Report. ,vol. 63, pp. 95- 102 ,(2014)
S Dirmesropian, JG Wood, CR MacIntyre, AT Newall, A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly Human Vaccines & Immunotherapeutics. ,vol. 11, pp. 818- 825 ,(2015) , 10.1080/21645515.2015.1011954
Alicia M Fry, Elizabeth R Zell, Anne Schuchat, Jay C Butler, Cynthia G Whitney, Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. ,vol. 21, pp. 303- 311 ,(2002) , 10.1016/S0264-410X(02)00451-6
JANE E. SISK, Cost Effectiveness of Vaccination Against Pneumococcal Pneumonia: An Update Annals of Internal Medicine. ,vol. 104, pp. 79- 86 ,(1986) , 10.7326/0003-4819-104-1-79
Bo-Hyun Cho, Charles Stoecker, Ruth Link-Gelles, Matthew R. Moore, Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. ,vol. 31, pp. 6011- 6021 ,(2013) , 10.1016/J.VACCINE.2013.10.024
A Melegaro, WJ Edmunds, None, Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. ,vol. 22, pp. 4203- 4214 ,(2004) , 10.1016/J.VACCINE.2004.05.003
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Mahlon Raymund, J. Pekka Nuorti, Richard K. Zimmerman, Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine JAMA. ,vol. 307, pp. 804- 812 ,(2012) , 10.1001/JAMA.2012.169
Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Karlis Pauksens, Richard N. Greenberg, Thomas R. Jones, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmoele-Thoma, Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine Vaccine. ,vol. 31, pp. 3585- 3593 ,(2013) , 10.1016/J.VACCINE.2013.05.010
Susan S. Huang, Kristen M. Johnson, G. Thomas Ray, Peter Wroe, Tracy A. Lieu, Matthew R. Moore, Elizabeth R. Zell, Jeffrey A. Linder, Carlos G. Grijalva, Joshua P. Metlay, Jonathan A. Finkelstein, Healthcare utilization and cost of pneumococcal disease in the United States Vaccine. ,vol. 29, pp. 3398- 3412 ,(2011) , 10.1016/J.VACCINE.2011.02.088